Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study.

Background: The use of multiagent FOLFIRINOX chemotherapy for pancreatic adenocarcinoma in a neoadjuvant setting has been associated with an increased rate of complete pathological response (CPR) after surgery. This study investigated the long-term outcomes of patients with CPR in a multicenter setting to identify prognostic factors for overall survival (OS) and recurrence-free survival (RFS).

Methods: This retrospective cohort study examined biopsy-proven pancreatic adenocarcinomas with CPR after neoadjuvant chemotherapy or chemoradiotherapy and surgery, between January 2006 and December 2023 across 22 French and  2 Belgian centers.

Evaluation of GnRH- versus estradiol-based protocols for ovulation synchronization in postpartum Bos taurus grazing beef cows submitted to fixed-time artificial insemination.

This study compared the effect of a 7-day estradiol- and a 7-day GnRH-based FTAI protocol versus a presynchronized GnRH-based FTAI protocol (7 & 7 GnRH) on pregnancy per AI (P/AI) in multiparous postpartum Angus cows. Cows were blocked according to presence/absence of a CL, body condition score, and days postpartum and assigned randomly to one of three treatments: I) 7-day EB (n = 368), estradiol benzoate (EB) and intravaginal progesterone-(P4)-releasing device (IVPD) on Day -10, prostaglandin F (PG), equine chorionic gonadotropin (eCG) and estradiol cypionate (ECP) at IVPD removal on Day -3 with FTAI done on Day -1 (54 ± 2 h after IVPD removal); II) 7-day GnRH (n = 367), GnRH at IVPD insertion on Day -10, PG and eCG at IVPD removal on Day -3 with GnRH and FTAI on Day 0 (66 ± 2 h after IVPD removal); and III) 7 & 7 GnRH (n = 361), PG at IVPD insertion on Day -17, GnRH on Day -10, IVPD removal, PG and eCG on Day -3 with GnRH and FTAI on Day 0 (66 ± 2 h after IVPD removal). Preovulatory follicle diameter, corpus luteum (CL) presence, CL area, and P4 concentration were determined at IVPD removal, as well as estrus expression at FTAI and P/AI between 35 and 40 days after FTAI.

Reduction of sacsin levels in peripheral blood mononuclear cells as a diagnostic tool for spastic ataxia of Charlevoix-Saguenay.

Autosomal recessive spastic ataxia of Charlevoix-Saguenay is a rare neurodegenerative disease caused by biallelic variants in the gene encoding for sacsin. More than 200 pathogenic variants have been identified to date, most of which are missense. It is likely that the prevalence of autosomal recessive spastic ataxia of Charlevoix-Saguenay is underestimated due to the lack of an efficient diagnostic tool able to validate variants of uncertain significance.

Vitamin D affects the risk of disease activity in multiple sclerosis.

Background: Vitamin D (VitD) affects the risk of multiple sclerosis (MS), but the impact on disease activity is controversial. We assessed whether VitD is associated with the No-Evidence of Disease Activity-3 (NEDA-3) status at 2 years from disease-modifying treatment (DMT) start, and whether this association is causal or the result of confounding factors. Furthermore, we explored if a genetic predisposition to higher VitD levels affects the risk of disease activity.